3,242
Total Claims
$13.5M
Drug Cost
335
Beneficiaries
$40K
Cost/Patient
Risk Score Breakdown 11/100
Low (0)Moderate (15)Elevated (30)High (50+)
Cost per patient outlier+10
Score components are additive. Read full methodology
Peer Comparison vs. 8,541 Hematology-Oncology providers
-71%
Opioid rate vs peers
1.9% vs 6.3% avg
+196%
Cost per patient vs peers
$40K vs $14K avg
Opioid Prescribing
1.9%
Opioid Rate
60
Opioid Claims
$942
Opioid Cost
—
Long-Acting Rate
Brand vs Generic
100% generic
Brand: 0 claims · $0
Generic: 2,256 claims · $527K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Lenalidomide | 323 | $5.2M |
| Ibrutinib | 128 | $1.7M |
| Pomalidomide | 64 | $1.4M |
| Venetoclax | 129 | $1.3M |
| Ruxolitinib Phosphate | 76 | $1.3M |
| Dasatinib | 47 | $572K |
| Eltrombopag Olamine | 25 | $341K |
| Lenalidomide | 21 | $288K |
| Bosutinib | 11 | $227K |
| Decitabine/Cedazuridine | 18 | $145K |
| Nilotinib Hcl | 14 | $142K |
| Imatinib Mesylate | 61 | $126K |
| Zanubrutinib | 17 | $121K |
| Apixaban | 63 | $47K |
| Acyclovir | 715 | $13K |
Prescribing Profile
Patient Profile
74
Avg Age
45%
Female
2.33
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations.Methodology · About